Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Zimmer Biomet Holdings Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.86, while Zimmer Biomet Holdings Inc trades at $92.44 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| FNGU | ZBH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $107.71 |
52-Week Low | $13.73 | $79.58 |
Market Cap | — | $17.44B |
Enterprise Value | — | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $28.77, down 0.45% on the day. The technical picture is mixed, with moving averages signaling bullish momentum but oscillators and a high RSI indicating overbought conditions. Recent news highlights the extreme volatility and decay inherent to its leveraged structure, with one report noting a $10,000 position losing 16% in a single session in June 2026.
The outlook is dominated by the product's high-risk, tactical nature. The opportunity lies in capturing amplified gains during strong bullish trends in mega-cap tech. The primary risk is significant capital erosion during volatile or sideways markets due to daily resetting leverage and compounding costs, making it unsuitable for long-term holding.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
